Ethos Technologies Inc. - Class A Common Stock (NQ:LIFE)

44.12 +1.50 (+3.51%)

Delayed Quote Updated: 10:11 AM EST, Nov 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ethos Technologies Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 Next >

Beat of Life Entertainment's 'Diya Jalao Roshni Lao' Campaign: Lighting Up Lives and Preserving Tradition!

November 13, 2023

The "Diya Jalao Roshni Lao" campaign was initiated by the Beat of Life Entertainment company in 2022. Its aim is to draw people's attention to our culture, the hard work of potters, hope, their lives,...

Via IssueWire

Topics Religion

aTyr Pharma to Present at November Investor Conferences

November 01, 2023

From aTyr Pharma, Inc.

Via GlobeNewswire

aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD

October 31, 2023

Multiple centers in the U.S. are open for enrollment

From aTyr Pharma, Inc.

Via GlobeNewswire

Analyst Expectations for aTyr Pharma's Future ↗

September 21, 2023

Via Benzinga

The Latest Analyst Ratings for aTyr Pharma ↗

May 23, 2023

Via Benzinga

aTyr Pharma: Q1 Earnings Insights ↗

May 09, 2023

Via Benzinga

Where aTyr Pharma Stands With Analysts ↗

March 10, 2023

Via Benzinga

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

September 11, 2023

From aTyr Pharma, Inc.

Via GlobeNewswire

$12M Bet On This Trucking Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗

August 02, 2023

The Dow Jones closed higher on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks...

Via Benzinga

aTyr Pharma's Cash Runway Secured till 2026, Despite Lack of Material Catalysts: Oppenheimer Analyst ↗

July 05, 2023

Oppenheimer has downgraded aTyr Pharma Inc (NASDAQ: LIFE) to Perform from Outperform, citing a few material catalysts in the next few quarters.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023 ↗

July 05, 2023

Via Benzinga

aTyr Pharma's Earnings: A Preview ↗

March 08, 2023

Via Benzinga

aTyr Pharma: Q2 Earnings Insights ↗

August 15, 2022

aTyr Pharma (NASDAQ:LIFE) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023 ↗

June 28, 2023

Bard AI has consistently outperformed, and it has identified seven growth stocks that it believes will deliver triple-digit returns.

Via InvestorPlace

3 Stocks and Cryptos With the Highest Potential Returns ↗

May 07, 2023

If you're only worried about upside, these stocks and cryptos have some of the highest possible returns in the market.

Via InvestorPlace

7 Hot Growth Stocks Poised to Triple in 2023 ↗

May 05, 2023

These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher.

Via InvestorPlace

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank ↗

March 11, 2023

The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

February 09, 2023

We're starting off another day of trading with a look at the biggest pre-market stock movers investors need to watch for Wednesday!

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 08, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 03, 2023

Via Benzinga

This Company Is Beginning A Pivotal Phase 3 EFZO-FIT™ Study. Could It Be A Much-Needed Treatment For Pulmonary Sarcoidosis? ↗

November 29, 2022

Most people may never have heard of sarcoidosis, an inflammatory disease that affects about 1.2 million people worldwide.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

November 18, 2022

On Friday, 64 companies achieved new lows for the year.

Via Benzinga

Beat Of Life Entertainment- A One Stop Solution For Internet Marketing

October 08, 2022

Internet marketing is the solution for business development in the digitalization era.

Via IssueWire

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary ↗

September 13, 2022

Via Benzinga

aTyr Pharma Gets FDA Fast Track Status For Systemic Sclerosis Candidate ↗

September 13, 2022

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 13, 2022

Via Benzinga

NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks ↗

August 16, 2022

Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading.

Via Benzinga

A Preview Of aTyr Pharma's Earnings ↗

August 12, 2022

aTyr Pharma (NASDAQ:LIFE) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors need to know before the announcement. Analysts estimate that aTyr Pharma...

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 11, 2022

Via Benzinga

Earnings Scheduled For August 15, 2022 ↗

August 15, 2022

Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.